Levaquin is an antibiotic drug that contains levofloxacin as its active ingredient. This drug, which comes in solution and oral dosage forms, is owned by Janssen Pharmaceuticals. Levaquin was first approved for market use on 21 October, 2004. It holds a total of 2 patents, both of which have already expired.
The generics of Levaquin are expected to be available after 26 August, 2022. This date is determined from the last patent of Levaquin, US6806256, titled 'Taste masked liquid pharmaceutical compositions' that expired on 26 February, 2022 and the same patent extending to 2022-08-26 due to a six-month pediatric extension (PED).
Levaquin is used to treat a variety of bacterial infections. It falls under the antibiotic category, specifically quinolone antibiotics. It works by stopping the growth of bacteria. levofloxacin, the active ingredient, contributes to the effectiveness of Levaquin by inhibiting the enzyme topoisomerase IV and DNA gyrase which are required for bacterial DNA replication, transcription, repair, and recombination.
Levaquin holds 2 patents, both of which are expired. The last patent, US6806256, was entitled 'Taste masked liquid pharmaceutical compositions' and expired on 2022-02-26 but was extended to 2022-08-26 due to a pediatric extension. With this information, we can predict that Levaquin generic will be available after this date. Below is the details of the patent: